{"name":"Idorsia Pharmaceuticals Ltd.","slug":"idorsia-pharmaceuticals-ltd","ticker":"","exchange":"","domain":"idorsia.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":15,"colorKey":"oncology","drugs":[{"name":"ACT-709478","genericName":"ACT-709478","slug":"act-709478","indication":"Other","status":"phase_1"},{"name":"ACT-709478 combined with midazolam","genericName":"ACT-709478 combined with midazolam","slug":"act-709478-combined-with-midazolam","indication":"Other","status":"phase_1"},{"name":"AC-082","genericName":"AC-082","slug":"ac-082","indication":"Other","status":"phase_1"},{"name":"AC-083","genericName":"AC-083","slug":"ac-083","indication":"Other","status":"phase_1"},{"name":"ACT-1004-1239","genericName":"ACT-1004-1239","slug":"act-1004-1239","indication":"Other","status":"phase_1"},{"name":"ACT-1014-6470","genericName":"ACT-1014-6470","slug":"act-1014-6470","indication":"Other","status":"phase_1"},{"name":"ACT-129968","genericName":"ACT-129968","slug":"act-129968","indication":"Insomnia disorder","status":"phase_3"},{"name":"ACT-132577","genericName":"ACT-132577","slug":"act-132577","indication":"Other","status":"phase_1"},{"name":"ACT-389949 200 mg","genericName":"ACT-389949 200 mg","slug":"act-389949-200-mg","indication":"Other","status":"phase_1"},{"name":"ACT-451840 1000 mg","genericName":"ACT-451840 1000 mg","slug":"act-451840-1000-mg","indication":"Other","status":"phase_1"},{"name":"ACT-451840 200 mg","genericName":"ACT-451840 200 mg","slug":"act-451840-200-mg","indication":"Other","status":"phase_1"},{"name":"ACT-451840:","genericName":"ACT-451840:","slug":"act-451840","indication":"Other","status":"phase_1"},{"name":"ACT-541468","genericName":"ACT-541468","slug":"act-541468","indication":"Insomnia","status":"phase_2"},{"name":"ACT541468","genericName":"ACT541468","slug":"act541468","indication":"Other","status":"phase_1"},{"name":"Pivlaz","genericName":"CLAZOSENTAN","slug":"clazosentan","indication":"Prevention of cerebrovascular spasm","status":"marketed"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"ACT-539313","genericName":"ACT-539313","slug":"act-539313","indication":"Treatment-resistant schizophrenia","status":"phase_2"},{"name":"ACT-709478 for oral use","genericName":"ACT-709478 for oral use","slug":"act-709478-for-oral-use","indication":"Treatment-resistant schizophrenia","status":"phase_2"}]}],"pipeline":[{"name":"ACT-709478","genericName":"ACT-709478","slug":"act-709478","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ACT-709478 combined with midazolam","genericName":"ACT-709478 combined with midazolam","slug":"act-709478-combined-with-midazolam","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AC-082","genericName":"AC-082","slug":"ac-082","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AC-083","genericName":"AC-083","slug":"ac-083","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ACT-1004-1239","genericName":"ACT-1004-1239","slug":"act-1004-1239","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ACT-1014-6470","genericName":"ACT-1014-6470","slug":"act-1014-6470","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ACT-129968","genericName":"ACT-129968","slug":"act-129968","phase":"phase_3","mechanism":"ACT-129968 is a selective orexin 2 receptor antagonist that promotes sleep by blocking wake-promoting signals in the brain.","indications":["Insomnia disorder"],"catalyst":""},{"name":"ACT-132577","genericName":"ACT-132577","slug":"act-132577","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ACT-389949 200 mg","genericName":"ACT-389949 200 mg","slug":"act-389949-200-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ACT-451840 1000 mg","genericName":"ACT-451840 1000 mg","slug":"act-451840-1000-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ACT-451840 200 mg","genericName":"ACT-451840 200 mg","slug":"act-451840-200-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ACT-451840:","genericName":"ACT-451840:","slug":"act-451840","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ACT-539313","genericName":"ACT-539313","slug":"act-539313","phase":"phase_2","mechanism":"ACT-539313 is a selective dopamine D2 receptor antagonist.","indications":["Treatment-resistant schizophrenia"],"catalyst":""},{"name":"ACT-541468","genericName":"ACT-541468","slug":"act-541468","phase":"phase_2","mechanism":"ACT-541468 is a selective orexin receptor antagonist.","indications":["Insomnia"],"catalyst":""},{"name":"ACT-709478 for oral use","genericName":"ACT-709478 for oral use","slug":"act-709478-for-oral-use","phase":"phase_2","mechanism":"ACT-709478 is a selective dopamine receptor D2/D3 antagonist.","indications":["Treatment-resistant schizophrenia","Major depressive disorder"],"catalyst":""},{"name":"ACT541468","genericName":"ACT541468","slug":"act541468","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Pivlaz","genericName":"CLAZOSENTAN","slug":"clazosentan","phase":"marketed","mechanism":"Endothelin-1 receptor","indications":["Prevention of cerebrovascular spasm"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxOTk8yR28zTkhXOFZabWNpQXJJenZpTDhKSTlJQV9TUlloSFhVUUp3X3B3UTJWVmVfb3BMbGV6NDFnSkJiN056ZFBvUXAxYmFULUd4RXdvTnVDSWt2ZVlCc2ZqU2d1OW9uU1lnaUg3UUhab2lwcmhDU0llaW9LTkd4b3FfR2JnZ2hXdWJ3ZmJRdkxXMUhTc0tSeEhOcEFxOEtuaE1LWWFER01zNC1X?oc=5","date":"2026-03-27","type":"trial","source":"vocal.media","summary":"Stanislav Kondrashov on Sandoz and Idorsia as Swiss Pharma Adjusts to a New Phase - vocal.media","headline":"Stanislav Kondrashov on Sandoz and Idorsia as Swiss Pharma Adjusts to a New Phase","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxPaGtGRV94TUl3aDZQM2RmVk1CNm1RRjZuWGJJTDhmUWRISWMtR2NqSFMzR1N4NnBCdHRDQ0RYMThMWHBJZk1RaDNlTlpKVmI1Tk9QNHhYTXVrbTFOUTR2cFdxcU5LZW01d0FyVHpkN19fYTU1WUJpSlZjb3p0TzFFa0ZrX2ZaYjVkeElvbUF3cmFtSWJTQzVuZFVLemVfTXJ4M3JhOWtkSzVFT3VWaDlpWmpRdW1FS2piNm1oNEhNb0lNRVVuUmEyNDBVVXZwYmdTRlJXazBudFdyeWNsRFJQR0tzeTNqcEtzU1E?oc=5","date":"2026-03-10","type":"deal","source":"GlobeNewswire","summary":"Idorsia expands QUVIVIQ’s global footprint through new partnership with Pharmalink - GlobeNewswire","headline":"Idorsia expands QUVIVIQ’s global footprint through new partnership with Pharmalink","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7wFBVV95cUxNQnR2RVc1em5uQzVtdTM3alhzcU5scUszYXBIbzFSb1dVSzdPV1hKSER4U2VyT0F3R2xjNTlGZGNoVk1YbGgxM3FueE8xdzJzY1NXZ3VMUkdTUWlWX1k1U1dNWDNxdWpYNG1QeG5rakY2RkFZZ2thbl9zS24tQk13ZDhWMDlrSmVseWllZnRqYVRFb3BDYWh1OFVnRFY3bzZDeFFTMld3Qy1XRk1Kc3hKVkgxWEhpX0ZwbVU3VzdtV21SejlaUTFkNlpJTTAwLUdIZXpjNWNhSWN3d1RJb3BMckxMTXJiZ1ZtRUsxSkVPOA?oc=5","date":"2026-01-28","type":"deal","source":"GlobeNewswire","summary":"Global expansion of Idorsia’s QUVIVIQ continues with EMS partnership for Latin America - GlobeNewswire","headline":"Global expansion of Idorsia’s QUVIVIQ continues with EMS partnership for Latin America","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNYWxkZlNBeVNCS0tNNjRaMnlQRnN5YU9FV1NnUjZaZW9HcTJ2QlFILWNmTm90VS1hMWhjUFhXSW41d01sazRlaFl6X252a0NFX0psNV9fUmF5c201aUl0bHZ6ZzR4X2lHNEFsdm1wanItT2RPd2ZmMVdkVHZmU01jSThPTmZhQWhPNnlVY09VRUJOMG1LRGc?oc=5","date":"2026-01-28","type":"pipeline","source":"The Pharma Letter","summary":"Global expansion of Idorsia’s Quviviq continues - The Pharma Letter","headline":"Global expansion of Idorsia’s Quviviq continues","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE05R0dLeTA0SnNlbDg1X19MZzlLYmdyVTZUcEJibko4QTQtS3hzZ0dGZXF4NUNLTHhjYUNGWW5FTHRmMmo3blFvSllrOFZsb1pzcHVienZNbzhhSlRjQ1B3MHJjVlVBQmVLYWZMRW9kdGVSb3F3ZGUtbFp1ejR3Zw?oc=5","date":"2026-01-06","type":"pipeline","source":"China Daily","summary":"Simcere eyes growing pharmaceutical niche - China Daily","headline":"Simcere eyes growing pharmaceutical niche","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxNSW9CSlFLX0o1ZTc5blFza1NRNm9tWmJPWmhNaFEwVlB0aUhzQVZkYXZtak11ZWl6VGd3WlBOSmhzT2VXSHRiNUVObDlTRUZucGQ0cVNra21vUTRVdlFnVEszZk1aakpVZ3R2RWhIRUNHcElwNlMtckNFai1JUXFFamRnMkcxQjNhbC1lS21Pcw?oc=5","date":"2025-12-09","type":"pipeline","source":"Yahoo Finance","summary":"Idorsia’s treatment for insomnia disorder wins the inaugural Prix Galien Bridges Award in the ‘Best Biotechnology & Pharmaceutical Product’ category - Yahoo Finance","headline":"Idorsia’s treatment for insomnia disorder wins the inaugural Prix Galien Bridges Award in the ‘Best Biotechnology & Phar","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxOOGhuem02cXlWWVV0LVl0eUJNY3k0aHhEYXh1dzkweU5PLTdmYXRpeEN1YThJOUhMTm96SVF3d3MzR3lLVXN5b3NmRXVSNlU4c0hOWlBTSHlRWVNwcEEwN0JjWWNtVXEyUjBFc1N6TkViLUVxV1VuV2RBZncwSEZuekROY05IWlRicVVqbUtVV0wwdUppVnNnM0JCejFKaXdnc1F6dklhakp4TDRTcVpOaHNCanhvWEU?oc=5","date":"2025-02-26","type":"deal","source":"Pharmaceutical Technology","summary":"Idorsia’s Tryvio deal collapses, forcing company to find cash urgently - Pharmaceutical Technology","headline":"Idorsia’s Tryvio deal collapses, forcing company to find cash urgently","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxOcHpvbEs4RWZsTnhjTDNjUkpxX3Q5RzhMTGQzRmdGZkV3c2ZPOXRjQ1M1czdONVMzemtGb096cmhOalF3Rm9kY2o1by0xV2FvQnlvRDZiRlN6VGhXbFF3a0phZVc4SmlDYjZsZzlqZnlMUkhYcHRDTkN4X3h6OWFNM0VEM2lrMktWN2RVV25LWQ?oc=5","date":"2024-12-20","type":"pipeline","source":"Precedence Research","summary":"Nxera Pharma and Shionogi Launch QUVIVIQ in Japan for Insomnia Treatment - Precedence Research","headline":"Nxera Pharma and Shionogi Launch QUVIVIQ in Japan for Insomnia Treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxPRWR0cmJMdEtmX1h6WkVMaUlKcXdJcndRdVlPejVmUlkyRVdyS2dsc2RBeXVkLUw5aldyV25NNGdsSmNWRk04WWZadk0tVllRcU1Oa1AwNWs1cWlDUDY4OTBTU0dETG1CdEtWS0x6cC1BX2RRMmFzMVBUaWZpWFFETERhTE9oOTZmc0toZXpuZWROZm5rVVR4cmg1dncyaVJSZG9KZzVNcWtpRVZianRaZVVOQ2lncG9ISWZpY2hjWlBqdw?oc=5","date":"2024-11-27","type":"pipeline","source":"Pharmaceutical Technology","summary":"Idorsia plans further job cuts and asset sale in latest cost-saving measures - Pharmaceutical Technology","headline":"Idorsia plans further job cuts and asset sale in latest cost-saving measures","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxQaWNiTWdEOGQ5ZGxWVEY3aFdkUVJ1bjladG9tXzhHVnppZmFFTExPUV85aVZzRnZ2UTNLZzQ2d0RtOW5xSVBid3lnd2s4Ym02WklfUkZnZ0FxT1kta1JqOGtOV05jUlJoYWFRZGlmd0tsSDB1eGhucExlNkpuSGZhOTNTMFBRQVR0?oc=5","date":"2024-03-22","type":"regulatory","source":"pharmaphorum","summary":"Idorsia first-in-class hypertension drug gets FDA okay - pharmaphorum","headline":"Idorsia first-in-class hypertension drug gets FDA okay","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxQUG53N2FiaXRPYWZRaHczaEFHM0doV3Zka2ZPcGxaVndnQ3hOeHVpMXBPbldabTlMSGhCX0VQanpmMkRuUmlLczZhMnh0djY1aUt3X3QxWFc2X3JQXzRmV1VfWXVwRlhBM2xpU2ItSHUwVGNQZXBmSklZNUVDeUJBd0RQaDNQXzVMU19aaElnVW5USktUb3c1SENJaUJRVVNOWUxLdFFwWU5BdGo4S0JPVHNGYThrQ3Z3bW0zZm5xX000RC13OVZjU1ZwVUpKbXJlZ25V?oc=5","date":"2023-07-20","type":"deal","source":"orrick.com","summary":"‘Truly Transformational:’ Sosei Heptares Acquires Idorsia’s Pharmaceuticals Business in Japan and APAC (ex-China) - orrick.com","headline":"‘Truly Transformational:’ Sosei Heptares Acquires Idorsia’s Pharmaceuticals Business in Japan and APAC (ex-China)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAJBVV95cUxNOVl5aHotc2tmUzBYNFNGOThkUmxJQ0lxazFkS3Z6ZkJLb1hDVjNCZktpVHdwMDhGSnAzMFhCSDJJM200SmxvNmlyeDdCemJzbGRrVFNWcWloWEVySWh5aWJOUFBDcDdxN1pFT2xZeXdjQUk3c1NzWWszV1Q5aXhOU0FnX2VKQzhkeC16aGw3WnlqUkN1bXhFYWJZNWkzZFl3OTlpNG1fdEVNUnlPWG92XzlfZXg4bENFeVVGRlBGQkN6Y3dvOU1LOXJOeUNWZFhBdzVtaWgyYzFtZllRbVpmcHhNdkw1dDBZXzFfbHpwTkJ0Y3ZzX3B4ajJhY2x4ZnF4Vk9CT192N2N3b1ZmenJaZQ?oc=5","date":"2022-05-13","type":"deal","source":"prnewswire.com","summary":"Idorsia U.S. Announces First Wave of Patients Prescribed QUVIVIQ (daridorexant) through Partnership with Pharmacy Services Provider - prnewswire.com","headline":"Idorsia U.S. Announces First Wave of Patients Prescribed QUVIVIQ (daridorexant) through Partnership with Pharmacy Servic","sentiment":"neutral"}],"patents":[],"drugCount":17,"phaseCounts":{"phase_1":12,"phase_3":1,"phase_2":3,"marketed":1},"enrichmentLevel":0,"visitCount":6,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}